Abbott starts ZoMaxx stent trial

Interventional device developer Abbott Vascular Devices (AVD), a subsidiary of Abbott Laboratories of Abbott Park, IL, has enrolled the first patient in its ZoMaxx I drug-eluting coronary stent clinical trial.

ZoMaxx I is a 400-patient prospective randomized clinical trial that will be conducted in more than 30 centers in Europe, Australia, and New Zealand. The study compares AVD's ZoMaxx drug-eluting coronary stent to the Taxus Express2 drug-eluting stent from interventional device firm Boston Scientific of Natick, MA. The study has a primary end point of nine-month in-segment late loss, a measurement of the narrowing of a vessel.

Enrollment is expected to continue through the first quarter of 2005, the firm said.

By staff writers
September 17, 2004

Related Reading

Abbott debuts StarClose, May 26, 2004

Abbott launches Perclose ProGlide, May 13, 2004

Abbott Labs launches endovascular unit, January 28, 2004

Abbott finishes Jomed deal, July 1, 2003

Abbott facility to produce Adenoscan, March 3, 2000

Copyright © 2004

Page 1 of 180
Next Page